A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

Also called NCT04784442

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04784442
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04784442. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-24 (actual); primary completion 2022-04-18 (actual). Results posted on 2024-03-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
180mg of ETC-1002(bempedoic acid)
Intervention (Drug)
120mg of ETC-1002(bempedoic acid)
Intervention (Drug)
60mg of ETC-1002(bempedoic acid)
Intervention (Drug)
Placebo
Lead sponsor
Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04784442
Content hash
414c4b66f7177744881b4ddca2beeb3376ad45bb8974ff82708ef44d24fc4371